JP4153421B2 - 内皮細胞による毛管の形成を阻害し得るアンチセンスオリゴヌクレオチド - Google Patents

内皮細胞による毛管の形成を阻害し得るアンチセンスオリゴヌクレオチド Download PDF

Info

Publication number
JP4153421B2
JP4153421B2 JP2003505336A JP2003505336A JP4153421B2 JP 4153421 B2 JP4153421 B2 JP 4153421B2 JP 2003505336 A JP2003505336 A JP 2003505336A JP 2003505336 A JP2003505336 A JP 2003505336A JP 4153421 B2 JP4153421 B2 JP 4153421B2
Authority
JP
Japan
Prior art keywords
disease
angiogenesis
oligonucleotide
neovascularization
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003505336A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004538272A (ja
JP2004538272A5 (enExample
Inventor
アル−マームード サルマン
Original Assignee
ジーン シグナル インターナショナル ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーン シグナル インターナショナル ソシエテ アノニム filed Critical ジーン シグナル インターナショナル ソシエテ アノニム
Publication of JP2004538272A publication Critical patent/JP2004538272A/ja
Publication of JP2004538272A5 publication Critical patent/JP2004538272A5/ja
Application granted granted Critical
Publication of JP4153421B2 publication Critical patent/JP4153421B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
JP2003505336A 2001-06-14 2002-06-14 内皮細胞による毛管の形成を阻害し得るアンチセンスオリゴヌクレオチド Expired - Fee Related JP4153421B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0107805A FR2826010B1 (fr) 2001-06-14 2001-06-14 Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires par les cellules endotheliales
PCT/FR2002/002067 WO2002103014A2 (fr) 2001-06-14 2002-06-14 Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires

Publications (3)

Publication Number Publication Date
JP2004538272A JP2004538272A (ja) 2004-12-24
JP2004538272A5 JP2004538272A5 (enExample) 2005-12-22
JP4153421B2 true JP4153421B2 (ja) 2008-09-24

Family

ID=8864317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003505336A Expired - Fee Related JP4153421B2 (ja) 2001-06-14 2002-06-14 内皮細胞による毛管の形成を阻害し得るアンチセンスオリゴヌクレオチド

Country Status (13)

Country Link
US (3) US7417033B2 (enExample)
EP (2) EP1409672B1 (enExample)
JP (1) JP4153421B2 (enExample)
AT (1) ATE435911T1 (enExample)
AU (1) AU2002345669B9 (enExample)
CA (1) CA2451874C (enExample)
CY (1) CY1109464T1 (enExample)
DE (1) DE60232883D1 (enExample)
DK (1) DK1409672T3 (enExample)
ES (1) ES2331835T3 (enExample)
FR (1) FR2826010B1 (enExample)
PT (1) PT1409672E (enExample)
WO (1) WO2002103014A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007031277A2 (en) * 2005-09-14 2007-03-22 Medizinische Universität Wien Means and methods for diagnosing endometriosis
US8032556B1 (en) * 2008-03-07 2011-10-04 Symantec Corporation Systems and methods for user profile data delivery
US8470997B2 (en) 2009-02-05 2013-06-25 Gene Signal International Sa Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization
US8580947B2 (en) 2009-02-05 2013-11-12 Gene Signal International Sa Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization
US20120041047A1 (en) * 2010-08-10 2012-02-16 Gene Signal International Sa Injectable Pharmaceutical Composition for Preventing, Stabilizing and/or Inhibiting Pathological Neovascularization-Related Conditions
CA2840143A1 (en) 2011-06-30 2013-01-03 Gene Signal International Sa Composition comprising inhibitors of irs-1 and of vegf
EP2540828A1 (en) 2011-06-30 2013-01-02 Gene Signal International SA Composition comprising inhibitors of IRS-1 and of VEGF
US9682144B2 (en) 2011-06-30 2017-06-20 Gene Signal International, Sa Composition comprising inhibitors of IRS-1 and of VEGF
US9359604B2 (en) * 2012-07-03 2016-06-07 Gene Signal International Sa Inhibitor of IRS-1 for treating skin disorders
US10052343B1 (en) 2017-02-03 2018-08-21 Gene Signal International Sa Sterile formulation comprising a stable phosphorothioate oligonucleotide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0572508A4 (en) * 1991-01-18 1995-03-29 Joslin Diabetes Center Inc NUCLEIC ACID ENCODING THE INSULIN RECEPTOR SUBSTRATE-1 (IRS-1), IRS-1 PROTEIN, DISEASES AND THERAPY ASSOCIATED WITH IRS-1 METABOLISM.
FR2733913B1 (fr) * 1995-05-09 1997-08-01 Sanofi Sa Sequence d'adn a titre de medicament, et compositions pharmaceutiques en contenant
EP1010433A4 (en) * 1997-09-29 2004-09-22 Daiichi Seiyaku Co MEDICINE FOR DISEASES CAUSED BY INSULIN RESISTANCE
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
WO2000070070A1 (en) * 1999-05-18 2000-11-23 Dnavec Research Inc. Paramyxoviridae virus vector defective in envelope gene

Also Published As

Publication number Publication date
EP2166095A2 (fr) 2010-03-24
WO2002103014A2 (fr) 2002-12-27
WO2002103014A3 (fr) 2004-02-26
EP2166095A3 (fr) 2012-01-04
EP1409672A2 (fr) 2004-04-21
PT1409672E (pt) 2009-11-04
JP2004538272A (ja) 2004-12-24
US20090082292A1 (en) 2009-03-26
US20040162257A1 (en) 2004-08-19
CA2451874A1 (fr) 2002-12-27
DK1409672T3 (da) 2009-11-09
FR2826010B1 (fr) 2005-02-25
EP1409672B1 (fr) 2009-07-08
CA2451874C (fr) 2013-07-30
US7855184B2 (en) 2010-12-21
US8828959B2 (en) 2014-09-09
AU2002345669B9 (en) 2006-06-29
AU2002345669B2 (en) 2006-02-02
CY1109464T1 (el) 2014-08-13
DE60232883D1 (de) 2009-08-20
ES2331835T3 (es) 2010-01-18
FR2826010A1 (fr) 2002-12-20
US7417033B2 (en) 2008-08-26
US20080293658A1 (en) 2008-11-27
ATE435911T1 (de) 2009-07-15

Similar Documents

Publication Publication Date Title
US8828959B2 (en) Antisense oligonucleotides capable of inhibiting the formation of capillary tubes by endothelial cells
Zieske et al. Activation of epidermal growth factor receptor during corneal epithelial migration
JP5705890B2 (ja) コネキシンに対するアンチセンスヌクレオチドを含む配合物
Bochaton-Piallat et al. TGF-β1, TGF-β receptor II and ED-A fibronectin expression in myofibroblast of vitreoretinopathy
Campana et al. Exogenous erythropoietin protects against dorsal root ganglion apoptosis and pain following peripheral nerve injury
KR100304033B1 (ko) 세포증식질환치료용약제학적조성물
Daniels et al. Expression of type VI collagen in uveal melanoma: its role in pattern formation and tumor progression
Mahmood et al. Interactions between retinoids and TGF β s in mouse morphogenesis
PT640143E (pt) Inibidores da sintese de adn derivados de celulas senescentes
EP2323637A1 (en) Treatment of fibrotic eye disorders
JP2010270156A (ja) 虚血性疾患の予防または治療剤
EP1005538B1 (en) Potassium channel proteins for use in gene therapy for alleviating erectile dysfunction
CHONG et al. An immunohistochemical study of an autosomal dominant feline rod/cone dysplasia (Rdy cats)
Kuo et al. Dehydrated form of plasmid expressing basic fibroblast growth factor–polyethylenimine complex is a novel and accurate method for gene transfer to the cornea
JP2021505544A (ja) 眼線維症の処置のためのｍｉＲ２９模倣物
JP3983271B1 (ja) エフリンｂ２を用いた新生血管抑制方法
JP2002523380A (ja) 平滑筋細胞緊張調節用の遺伝子治療
AU2003200309B2 (en) Pharmaceutical Composition for Preventing or Treating Ischaemic Diseases
WO2022168971A1 (ja) 哺乳動物における着床率の調節方法、哺乳動物における着床率の向上剤、及び医薬
JP2004500012A (ja) ラミニン５、１３及び１４並びにそれらの利用
Potts Disruption of Msx-1, Msx-2, and HNF-3 (beta) using antisense oligonucleotide technology and mouse whole embryo culture produces craniofacial and axial malformations

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041208

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20060523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070817

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071108

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080606

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080703

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4153421

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110711

Year of fee payment: 3

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20091120

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A072

Effective date: 20100316

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120711

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130711

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees